Endonovo Therapeutics Inc (ENDV)

[Biotech_Tradez]

BUYER BEWARE: $2.9 Million in debt to be converted at a 50% discount.

ENDV just lost a lawsuit and filed the following today:

On November 14, 2024, in a case entitled Trillium Partners, L.P. (“Trillium”) v Endonovo Therapeutics, Inc. (the “Company”) in the Circuit Court for the 17th Judicial Circuit in and for Broward County Florida (Case No CACE24009960), the court issued an order (the “Order”) approving a settlement of $2,896,956.15 of the Company’s outstanding debt in exchange for the issuance of shares at a 50% discount to market under Section 3(a)(10) of the Securities Act of 1933, as amended. The shares, when issued pursuant to the Order, will be free of any restriction and be marketable securities. As a result of the Order, the Company’s outstanding indebtedness was reduced from approximately $2,896,956.15. The sale of shares under the Order, which has not yet commenced, may have a depressive affect on the market for the Company’s shares.